---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-073089"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:54:58.881741+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INmune Bio posts $24.5M net loss, CEO replaced; INKmune trial meets endpoints

## Summary
- Net loss $24.5M in Q2 2025 vs $9.7M in Q2 2024; includes $16.5M impairment of in-process R&D intangibles.
- CEO RJ Tesi retires; David Moss appointed President & CEO; Cory Ellspermann Interim CFO.
- INKmune CaRe PC trial in mCRPC met primary safety and secondary endpoints; trial closed to enrollment.
- XPro MINDFuL trial missed primary cognitive endpoints overall; positive trends in enriched biomarker subset.
- Cash $33.4M as of June 30; completed $19M registered direct offering.

## SEC filing metadata
- accession: 0001213900-25-073089
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025073089/0001213900-25-073089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025073089/ea0251921-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-073089
- JSON: https://secwatch.observer/filing/0001213900-25-073089.json
- Plain text: https://secwatch.observer/filing/0001213900-25-073089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.